Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01313923 · ClinicalTrials.gov registry record · Early Phase 1
Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus
A Early Phase 1 study, sponsored by University of California, Irvine.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT01313923: Clinical Trial Early Phase 1 study, sponsored by University of California, Irvine.
NCT01313923 is a Early Phase 1 study that was terminated before completion, run by University of California, Irvine. The registered enrollment target is 3 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01313923, a Early Phase 1 study, was terminated before completion, sponsored by University of California, Irvine.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this research is to study alternative treatments for the skin disease pemphigus (a rare autoimmune blistering disorder of the skin) by using sirolimus, an immunosuppressive drug. Immunosuppressive drugs inhibit or prevent the activity of the immune system and are commonly used to treat autoimmune diseases, inflammatory diseases, and organ transplantation rejection.
Primary Outcome
Measurement of disease severity will be quantified using ABSIS (Autoimmune Bullous Skin Disorder Intensity Score). Improvement in disease control is quantified by the maintenance or improvement of ABSIS score while reducing steroid dosage. No results as study has been terminated early by the investigator.
Interventions
- DRUG Sirolimus (formerly known as Rapamycin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2011-02 |
| Est. Completion | 2014-10 |
| Phase | Early Phase 1 |
Why NCT01313923 stopped before completion
NCT01313923 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Sirolimus (formerly known as Rapamycin) is the first listed.
NCT01313923 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01313923 about?
NCT01313923 is a clinical study titled "Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus". The purpose of this research is to study alternative treatments for the skin disease pemphigus (a rare autoimmune blistering disorder of the skin) by using sirolimus, an immunosuppressive drug. Immunosuppressive drugs inhibit or prevent the activity of the immune system and are commonly used to trea...
What is the current status of trial NCT01313923?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2011-02. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01313923?
The interventions under investigation include: Sirolimus (formerly known as Rapamycin) (DRUG).
Who is sponsoring clinical trial NCT01313923?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01313923's enrollment target sits among peer trials
3 1948th of 2000 higher than 28 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia